-
Genetic causes of lymphatic disorders: recent updates on the clinical and molecular aspects of lymphatic disease. Curr. Opin. Cardiol. (IF 2.3) Pub Date : 2024-03-14 Catharine Bowman, Stanley G Rockson
The lymphatic system facilitates several key functions that limit significant morbidity and mortality. Despite the impact and burden of lymphatic disorders, there are many remaining disorders whose genetic substrate remains unknown. The purpose of this review is to provide an update on the genetic causes of lymphatic disorders, while reporting on newly proposed clinical classifications of lymphatic
-
Leaders need to look in the mirror. Curr. Opin. Cardiol. (IF 2.3) Pub Date : 2024-03-12 Josh Koch
There is commonly a discrepancy between optimal physician leader behavior and actual physician leader behavior. Identifying and addressing this discrepancy is essential to optimize culture in high-risk care units.
-
Predictive utility of remnant cholesterol in atherosclerotic cardiovascular disease. Curr. Opin. Cardiol. (IF 2.3) Pub Date : 2024-03-11 Spencer D Proctor, Maggie Wang, Donna F Vine, Paolo Raggi
Remnant cholesterol (RC) is the cholesterol carried in lipoproteins derived from the catabolism of chylomicrons and very low-density lipoproteins. Evidence supporting the causal relationship of RC with atherosclerotic cardiovascular disease (ASVD) is accumulating rapidly. The number of impactful contributions to this field are increasing and provide a pathophysiological insight into the current residual
-
Pemafibrate and other triglyceride-lowering therapies to reduce risk of cardiovascular and metabolic disease. Curr. Opin. Cardiol. (IF 2.3) Pub Date : 2024-03-06 Michael Miller
Although high triglycerides are consistently associated with elevated risk of cardiovascular disease (CVD), therapies that reduce triglyceride levels have inconsistently translated into reduced CVD risk.
-
Effects of bempedoic acid on markers of inflammation and Lp(a). Curr. Opin. Cardiol. (IF 2.3) Pub Date : 2024-03-05 Sukhila Reddy, Abhizith Deoker
To study the effect of bempedoic acid on markers of inflammation and lipoprotein (a) to help determine if the drug would be useful to treat patients with elevated cardiovascular risks and residual cardiovascular risk despite optimal low-density lipoprotein cholesterol (LDL-C) levels.
-
Resistant hypertension. Curr. Opin. Cardiol. (IF 2.3) Pub Date : 2024-03-05 Farnoosh Shariati, Nitin Tandan, Carl J Lavie
Resistant hypertension (RH) is characterized by persistently elevated blood pressure despite the concurrent use of three antihypertensive medications, including a diuretic, at optimal doses. This clinical phenomenon poses a significant burden on healthcare systems worldwide due to its association with increased cardiovascular disease morbidity and mortality.
-
Clinical impact of genetic testing for lipid disorders. Curr. Opin. Cardiol. (IF 2.3) Pub Date : 2024-03-01 Emir Muzurović, Sanja Borozan, Manfredi Rizzo
Genetic testing is increasingly becoming a common consideration in the clinical approach of dyslipidemia patients. Advances in research in last decade and increased recognition of genetics in biological pathways modulating blood lipid levels created a gap between theoretical knowledge and its applicability in clinical practice. Therefore, it is very important to define the clinical justification of
-
Short and long-term complications of hypertensive disorders of pregnancy: lifelong cardiovascular risks we cannot ignore. Curr. Opin. Cardiol. (IF 2.3) Pub Date : 2024-02-22 Cara E Saxon, Julia Bast, Josephine C Chou
Hypertensive disorders of pregnancy (HDP) pose a significant threat to maternal cardiovascular health, with emerging research shedding light on the enduring risks beyond the gestational period. This review highlights updates regarding cardiovascular risks associated with HDP and their implications for long-term health.
-
Metabolic basis of cardiac dysfunction in cancer patients. Curr. Opin. Cardiol. (IF 2.3) Pub Date : 2024-02-22 Jane C Figueiredo, Neil Adri Bhowmick, Anja Karlstaedt
The relationship between metabolism and cardiovascular diseases is complex and bidirectional. Cardiac cells must adapt metabolic pathways to meet biosynthetic demands and energy requirements to maintain contractile function. During cancer, this homeostasis is challenged by the increased metabolic demands of proliferating cancer cells.
-
The role of genetic testing in Marfan syndrome. Curr. Opin. Cardiol. (IF 2.3) Pub Date : 2024-02-22 Emanuele Monda, Martina Caiazza, Giuseppe Limongelli
This review aims to delineate the genetic basis of Marfan syndrome (MFS) and underscore the pivotal role of genetic testing in the diagnosis, differential diagnosis, genotype-phenotype correlations, and overall disease management.
-
Sleep-disordered breathing in heart failure. Curr. Opin. Cardiol. (IF 2.3) Pub Date : 2024-02-20 Gregory R Jackson, Justin Durland, Frank Hoyland
This review addresses the evolving intersection of sleep-disordered breathing (SDB) and heart failure, a topic of increasing clinical significance due to the high prevalence of SDB in heart failure patients and its impact on morbidity and mortality. It reflects recent advancements in diagnostic methodologies and therapeutic strategies. It emphasizes the need for heightened awareness among healthcare
-
Decongestion (instead of ultrafiltration?). Curr. Opin. Cardiol. (IF 2.3) Pub Date : 2024-02-19 Art Schuermans, Frederik H Verbrugge
To summarize the contemporary evidence on decongestion strategies in patients with acute heart failure (AHF).
-
Intravenous iron in patients with iron deficiency and heart failure: a review of modern evidence. Curr. Opin. Cardiol. (IF 2.3) Pub Date : 2024-02-15 Stormi E Gale, Andrew Willeford, Katherine Sandquist, Kristin Watson
Iron deficiency is common in patients with heart failure, affecting up to half of ambulatory patients and an even greater percentage of patients admitted for acute decompensation. Iron deficiency in this population is also associated with poor outcomes, including worse quality of life in addition to increased hospitalizations for heart failure and mortality. Evidence suggests that patients with iron
-
Simulating mitral repair: lessons learned. Curr. Opin. Cardiol. (IF 2.3) Pub Date : 2024-02-03 Abigail White, Anna Zarzycki, Gianluigi Bisleri
With the growing complexity of cardiac surgical cases, increased focus on patient safety, and minimally invasive techniques, simulation-based training has experienced a renaissance. This review highlights important elements of simulation-based training, focusing specifically on available simulators for mitral valve repair and the uses for simulation.
-
Beyond Weight Loss: the Emerging Role of Incretin-Based Treatments in Cardiometabolic HFpEF. Curr. Opin. Cardiol. (IF 2.3) Pub Date : 2024-01-31 Federico Capone, Natasha Nambiar, Gabriele G Schiattarella
Incretin-based drugs are potent weight-lowering agents, emerging as potential breakthrough therapy for the treatment of obesity-related phenotype of heart failure with preserved ejection fraction (HFpEF). In this review article, we will discuss the contribution of weight loss as part of the benefits of incretin-based medications in obese patients with HFpEF. Furthermore, we will describe the potential
-
Obesity/cardiometabolic phenotype of heart failure with persevered ejection fraction: mechanisms to recent trials. Curr. Opin. Cardiol. (IF 2.3) Pub Date : 2024-01-26 Raj Verma, Nitish K Dhingra, Kim A Connelly
Heart failure with preserved ejection fraction (HFpEF) is a leading and growing cause of morbidity and mortality globally. Of the various phenotypes identified, the obesity (or cardiometabolic) phenotype appears to be most common. The purpose of this review is to provide the clinician with an abridged understanding of recent developments that have elucidated obesity/visceral adiposity as a central
-
A review of the contemporary use of inotropes in patients with heart failure. Curr. Opin. Cardiol. (IF 2.3) Pub Date : 2023-12-27 Radhika Neicheril, David Snipelisky
The role of inotropes has evolved with its use now expanding over multiple indications including cardiogenic shock, low cardiac output states, bridging therapy to transplant or mechanical support, and palliative care. There remains no consensus as to the recommended inotrope for the failing heart. We aim to provide an overview of the recent literature related to inotrope therapy and its application
-
Wellness and burnout in cardiac surgery: not black and white. Curr. Opin. Cardiol. (IF 2.3) Pub Date : 2023-12-21 Aliya Izumi, Akachukwu Nwakoby, Raj Verma, Bobby Yanagawa
Despite a growing emphasis on burnout in medicine, there remains a paucity of data in cardiac surgery. Herein, we summarize recent data on cardiac surgeon well being and identify factors for consideration in future burnout inquiries and management.
-
Worsening heart failure: a concept in evolution. Curr. Opin. Cardiol. (IF 2.3) Pub Date : 2023-12-19 Max Puthenpura, Jennifer Wilcox, W H Wilson Tang
Worsening heart failure (WHF) has developed as a unique definition within heart failure (HF) in recent years. It captures the disease as a dynamic process. This review describes what is currently known about WHF, why it should be considered a discrete scientific endpoint, and future directions for research.
-
A comprehensive overview of surgical and transcatheter therapies to treat tricuspid regurgitation in patients with heart failure. Curr. Opin. Cardiol. (IF 2.3) Pub Date : 2023-12-19 Vincent Chen, Omar Abdul-Jawad Altisent, Rishi Puri
The unique pathophysiologic considerations of severe tricuspid regurgitation (TR) have led to advancements in surgical and transcatheter treatments. The purpose of this review is to highlight the current surgical and transcatheter tricuspid valve interventions (TTVI) to functional TR.
-
Heart transplant donation after circulatory death: current status and implications. Curr. Opin. Cardiol. (IF 2.3) Pub Date : 2023-12-19 Savitri Fedson
The use of cardiac transplantation following circulatory death (DCD) has been limited worldwide. Concerns about cardiac function after warm ischemia and the potential for decreased graft function have been important considerations in this hesitancy. In addition, ethical and legal questions about the two widely used organ procurement methods have led to discussions and public education in many countries
-
Considerations & challenges of mitral valve repair in females: diagnosis, pathology, and intervention. Curr. Opin. Cardiol. (IF 2.3) Pub Date : 2023-12-07 Mimi Xiaoming Deng, Batol Barodi, Malak Elbatarny, Terrence M Yau
Disparities in mitral valve (MV) repair outcomes exist between men and women. This review highlights sex-specific differences in MV disease aetiology, diagnosis, as well as timing and type of intervention.
-
Which lesions are not amenable to tricuspid clipping? Curr. Opin. Cardiol. (IF 2.3) Pub Date : 2023-11-30 Shahrukh N Bakar, Neil P Fam
Tricuspid transcatheter edge-to-edge repair (T-TEER) has emerged as a well tolerated and effective therapeutic option for many patients with symptomatic severe tricuspid regurgitation at prohibitive surgical risk. However, there remain several important limitations to clip-based technology in the context of other rapidly emerging percutaneous treatment options for tricuspid regurgitation.
-
2023 Update on equity, diversity, and inclusion in Canadian cardiac surgery. Curr. Opin. Cardiol. (IF 2.3) Pub Date : 2023-11-08 Lina A Elfaki,Rosalind Groenewoud,Akachukwu Nwakoby,Areeba Zubair,Raj Verma,Bobby Yanagawa
PURPOSE OF REVIEW Despite efforts to diversify the medical field, cardiac surgery remains amongst the least diverse specialties. Specifically, the percentage of women and racial minorities has remained low in past few decades. This may impact prospective trainee recruitment and surgical care. This paper highlights recent efforts that aim to promote diversity and inclusion of the Canadian cardiac surgical
-
Low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol and apolipoprotein B for cardiovascular care. Curr. Opin. Cardiol. (IF 2.3) Pub Date : 2023-11-07 Selin Bilgic,Allan D Sniderman
PURPOSE OF REVIEW Some experts and consensus groups continue to argue that apolipoprotein B (apoB) should not be introduced broadly into clinical care. But, too often, the present approach to clinical care is not succeeding. An important reason for this failure, we believe, is that the conventional approach limits what the expert clinician can accomplish and is too complex, confusing, and contradictory
-
Cardiovascular disease prevention in women - the current state in 2023. Curr. Opin. Cardiol. (IF 2.3) Pub Date : 2023-11-06 Aarti Purohit,Yoo Jin Kim,Erin D Michos
PURPOSE OF REVIEW Cardiovascular disease (CVD) remains a leading cause of morbidity and mortality for women globally. The purpose of this review is to provide an updated overview of CVD prevention in women, focusing on what is currently understood about female-specific or female-predominant CVD risk factors and the importance of tailored strategies for risk assessment and medical interventions. RECENT
-
Measuring lipoprotein(a) for cardiovascular disease prevention - in whom and when? Curr. Opin. Cardiol. (IF 2.3) Pub Date : 2023-11-03 Peter E Thomas, Signe Vedel-Krogh, Børge G Nordestgaard
The aim of this study is to summarize major cardiovascular guideline recommendations on lipoprotein(a) and highlighting recent findings that emphasize how measuring lipoprotein(a) once in all adults is meaningful regardless of age, sex, comorbidities, or ethnicity.
-
Salt restriction for treatment of hypertension - current state and future directions. Curr. Opin. Cardiol. (IF 2.3) Pub Date : 2023-11-02 Philip Nolan, John W McEvoy
Given the adverse effects of excess dietary sodium chloride (also known as table salt) on blood pressure (BP) and cardiovascular disease (CVD), restriction of dietary sodium is recommended by numerous guidelines. The strictest of these recommend no more than 1.5 g/day of dietary sodium among hypertensive persons. However, average dietary sodium intake in the population is closer to 5 g/day and there
-
Left atrial appendage closure: the journey today and tomorrow. Curr. Opin. Cardiol. (IF 2.3) Pub Date : 2023-10-23 Marvin Louis Roy Lu,David Bowers De Lurgio
PURPOSE OF REVIEW This review aims to discuss the rationale behind the development of percutaneous LAAC devices as a treatment option for atrial fibrillation patients ineligible for long-term anticoagulation. The evolution of LAAC, from early experiences and challenges to risk mitigation and improved devices and techniques, will be examined. Furthermore, the review will explore our current understanding
-
Radiofrequency lesion formation prediction with contact force versus local impedance. Curr. Opin. Cardiol. (IF 2.3) Pub Date : 2023-10-10 Ziad F Issa
Safe and effective radiofrequency (RF) myocardial ablation requires real-time monitoring of lesion formation. Here, we review conventional and novel approaches proposed to guide titration of RF energy application.
-
Introduction to the coronary artery surgery section. Curr. Opin. Cardiol. (IF 2.3) Pub Date : 2023-10-05 Marc Ruel,Robert Roberts
-
The plaque hypothesis: understanding mechanisms of plaque progression and destabilization, and implications for clinical management. Curr. Opin. Cardiol. (IF 2.3) Pub Date : 2023-09-29 Mona E Ahmed, Diaa Hakim, Peter H Stone
Major adverse cardiac events (MACE) typically arise from nonflow-limiting coronary artery disease and not from flow-limiting obstructions that cause ischemia. This review elaborates the current understanding of the mechanism(s) for plaque development, progression, and destabilization and how identification of these high-risk features can optimally inform clinical management.
-
Impact of PCSK9 inhibitors on coronary atheroma phenotype following myocardial infarction: insights from intravascular imaging. Curr. Opin. Cardiol. (IF 2.3) Pub Date : 2023-09-26 Timothy Abrahams, Masashi Fujino, Adam J Nelson, Stephen J Nicholls
The aim of this study was to review the impact of combination lipid lowering with statins and proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors on coronary atherosclerosis using serial intravascular imaging.
-
Advances in cardiac pacing with leadless pacemakers and conduction system pacing. Curr. Opin. Cardiol. (IF 2.3) Pub Date : 2023-09-22 Sulaiman Somani, Albert J Rogers
The field of cardiac pacing has undergone significant evolution with the introduction and adoption of conduction system pacing (CSP) and leadless pacemakers (LLPMs). These innovations provide benefits over conventional pacing methods including avoiding lead related complications and achieving more physiological cardiac activation. This review critically assesses the latest advancements in CSP and LLPMs
-
Antiplatelet therapy around CABG: the latest evidence. Curr. Opin. Cardiol. (IF 2.3) Pub Date : 2023-09-22 Sigrid Sandner, Björn Redfors, Mario Gaudino
The optimal antiplatelet strategy in patients after coronary artery bypass graft (CABG) surgery is unclear. We review the evidence on the efficacy and safety of DAPT after CABG and discuss potential novel antiplatelet strategies that reduce the risk of bleeding without loss of efficacy.
-
Reconsideration of the definition of blanking period and significance of early recurrences after catheter ablation of atrial fibrillation. Curr. Opin. Cardiol. (IF 2.3) Pub Date : 2023-09-19 Songnan Wen, Yu Liao, Tejas S Khurana, Rong Bai
Early recurrence of atrial tachyarrhythmia (ERAT) during blanking period (BP) is not uncommon after catheter ablation of AF. Current guidelines and consensus statements recommend conservative treatment of ERAT. This review summarized recent studies, underlying mechanism and clinical managements of ERAT, and proposed a reconsideration of the definition and clinical significance of BP.
-
Coronary artery bypass grafting in left ventricular dysfunction: when and how. Curr. Opin. Cardiol. (IF 2.3) Pub Date : 2023-09-19 Gabriele M Iacona, Jules J Bakhos, Michael Z Tong, Faisal G Bakaeen
The surgical management of patients undergoing coronary artery bypass grafting (CABG) with low ejection fraction presents unique challenges that require meticulous attention to details and good surgical technique and judgement. This review details the latest evidence and best practices in the care of such patients.
-
Perspectives on pulsed field ablation: how to judge endpoints. Curr. Opin. Cardiol. (IF 2.3) Pub Date : 2023-09-12 Valeria Anglesio, Atul Verma
This review highlights pulse field ablation's (PFA) significance in treating atrial fibrillation. PFA uses short-pulsed electrical fields, offering safety advantages over thermal methods. Multicenter studies' findings on PFA's safety, efficiency, and efficacy, compared with thermal techniques, are discussed.
-
Neurologic impact of atrial fibrillation. Curr. Opin. Cardiol. (IF 2.3) Pub Date : 2023-09-08 Daniel R Feldman, Emily P Zeitler
Cognitive dysfunction is a complex condition that is becoming increasingly more prevalent. There has been growing acknowledgement that individuals with atrial fibrillation are at an increased risk of cognitive dysfunction beyond the association of age with both disorders. The purpose of this review is to explore the potential underlying mechanisms connecting atrial fibrillation and cognitive dysfunction
-
Disparity issues in coronary artery surgery. Curr. Opin. Cardiol. (IF 2.3) Pub Date : 2023-09-05 Gry Dahle
PURPOSE OF REVIEW Coronary artery disease is the third leading cause of mortality worldwide. Coronary artery surgery is an important treatment option. Certain groups such as people of color, those from lower socioeconomic backgrounds and women tend to have lower rates of receiving the surgery they need ( Fig. 1 ). RECENT FINDINGS Still there are disparities in treatment options for coronary artery
-
Vascular regenerative cells in cardiometabolic disease. Curr. Opin. Cardiol. (IF 2.3) Pub Date : 2023-08-31 Ehab Bakbak, Aishwarya Krishnaraj, Brady Park, Subodh Verma, David A Hess
This review will provide an overview of the recent literature linking the pathophysiology of cardiometabolic disease with the depletion and dysfunction of circulating vascular regenerative (VR) cell content. Moreover, we provide rationale for the use of VR cells as a biomarker for cardiovascular risk and the use of pharmacological agents to improve VR cell content.
-
Coronary microvascular dysfunction and heart failure with preserved ejection fraction: what are the mechanistic links? Curr. Opin. Cardiol. (IF 2.3) Pub Date : 2023-08-29 Aish Sinha, Haseeb Rahman, Divaka Perera
Heart failure with preserved ejection fraction (HFpEF) accounts for half of all heart failure presentations and is associated with a dismal prognosis. HFpEF is an umbrella term that constitutes several distinct pathophysiological entities. Coronary microvascular dysfunction (CMD), defined as the inability of the coronary vasculature to augment blood flow adequately in the absence of epicardial coronary
-
Designing the coronary artery bypass surgery operation of the future. Curr. Opin. Cardiol. (IF 2.3) Pub Date : 2023-08-25 Marc Ruel
This article discusses current shortcomings in coronary artery bypass surgery and ways to overcome them.
-
Preoperative optimization and rapid discharge after coronary artery bypass grafting. Curr. Opin. Cardiol. (IF 2.3) Pub Date : 2023-08-25 Menaka Ponnambalam, Rozen M Alex
This review discusses current guidelines and evidence-based care for the preoperative optimization of patients who are undergoing coronary artery bypass grafting (CABG) and for enabling rapid discharge after surgery.
-
Coronary artery calcium and sudden cardiac death: current evidence and future directions. Curr. Opin. Cardiol. (IF 2.3) Pub Date : 2023-08-24 Alexander C Razavi,Seamus P Whelton,Roger S Blumenthal,Laurence S Sperling,Michael J Blaha,Omar Dzaye
PURPOSE OF REVIEW To provide a summary of the current evidence and highlight future directions regarding coronary artery calcium (CAC) and risk of sudden cardiac death (SCD). RECENT FINDINGS Although up to 80% of all SCD is attributed to coronary heart disease (CHD), the subclinical atherosclerosis markers that help to improve SCD risk prediction are largely unknown. Recent observational data have
-
The evolving role of cardiopulmonary exercise testing in ischemic heart disease - state of the art review. Curr. Opin. Cardiol. (IF 2.3) Pub Date : 2023-08-22 Sundeep Chaudhry, Naresh Kumar, Ross Arena, Subodh Verma
Cardiopulmonary exercise testing (CPET) is the gold standard for directly assessing cardiorespiratory fitness (CRF) and has a relatively new and evolving role in evaluating atherosclerotic heart disease, particularly in detecting cardiac dysfunction caused by ischemic heart disease. The purpose of this review is to assess the current literature on the link between cardiovascular (CV) risk factors,
-
Glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide receptor co-agonists for cardioprotection, type 2 diabetes and obesity: a review of mechanisms and clinical data. Curr. Opin. Cardiol. (IF 2.3) Pub Date : 2023-08-21 Ronald M Goldenberg, Hwee Teoh, Subodh Verma
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are approved for the management of type 2 diabetes (T2D) and obesity, and some are recommended for cardiorenal risk reduction in T2D. To enhance the benefits with GLP-RA mono-agonist therapy, GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor co-agonists are in development to capitalize on the synergism of GLP-1 and GIP agonism. We
-
Transfusion thresholds in acute coronary syndromes. Curr. Opin. Cardiol. (IF 2.3) Pub Date : 2023-08-18 Nikhil Mistry, Helen Jiang, Kyle Chin, Gregory M T Hare, Subodh Verma, C David Mazer
Anemia is prevalent in patients with acute coronary syndromes. In this setting, there is uncertainty and controversy surrounding the optimal transfusion strategy for managing anemia. The goal of this review is to summarize the current clinical evidence, guidelines, and future directions for managing transfusion in acute coronary syndromes.
-
Clinical considerations and pathophysiological associations among obesity, weight loss, heart failure, and hypertension. Curr. Opin. Cardiol. (IF 2.3) Pub Date : 2023-08-01 Maria Irene Barillas-Lara, Christian C Faaborg-Andersen, Raymundo A Quintana, Juan Francisco Loro-Ferrer, Stacy A Mandras, Adrian daSilva-deAbreu
To describe the relationship between three pandemics: hypertension, obesity, and heart failure. From pathophysiology to treatment, understanding how these disease entities are linked can lead to breakthroughs in their prevention and treatment. The relevance of this review lies in its discussion of novel pharmacological and surgical treatment strategies for obesity and hypertension, and their role in
-
Antithrombotic treatment following percutaneous coronary intervention in patients with high bleeding risk. Curr. Opin. Cardiol. (IF 2.3) Pub Date : 2023-07-31 Zaid I Almarzooq, Nora M Al-Roub, Scott Kinlay
Review the clinical outcomes of different antithrombotic strategies in patients with high bleeding risk (HBR) after percutaneous coronary intervention (PCI).
-
Inclisiran and cardiovascular events: a comprehensive review of efficacy, safety, and future perspectives. Curr. Opin. Cardiol. (IF 2.3) Pub Date : 2023-07-27 Ahmed A Mohamed, Kausik K Ray
This review aims to offer an up-to-date evaluation of Inclisiran's (a small interfering RNA treatment) ability to decrease low-density lipoprotein cholesterol (LDL-C), as well as its safety and potential effects on decreasing cardiovascular risk.
-
The mitral valve in hypertrophic cardiomyopathy. Curr. Opin. Cardiol. (IF 2.3) Pub Date : 2023-07-14 James Malcolmson,Alex Shipolini,Saidi Mohiddin,Konstantinos Savvatis
PURPOSE OF REVIEW Whilst abnormally increased left ventricular wall thickness is the hallmark feature of hypertrophic cardiomyopathy (HCM), anomalies of the mitral valve and supporting apparatus are well documented. This review addresses the clinical importance of mitral valve abnormalities in HCM, their mechanistic associations with symptoms, and therapeutic strategies targeting mitral valve and apparatus
-
Evaluation and management of drug-eluting stent in-stent restenosis. Curr. Opin. Cardiol. (IF 2.3) Pub Date : 2023-07-13 Shane Parfrey,Vincent Siu,John J Graham,Ram Vijayaraghavan,Christopher Li,Jeffrey Pang,Sanjog Kalra,Vladimír Džavík,Harindra C Wijeysundera,Akshay Bagai,
PURPOSE OF REVIEW In-stent restenosis (ISR) is the most common cause of stent failure. Although the rate of ISR is significantly lower with contemporary drug-eluting stents (DES), it remains a challenging clinical entity to treat. RECENT FINDINGS In this review, we focus on a practical approach to management of DES ISR with intravascular imaging at its core, as supported by several recently published
-
Imaging cardiac hypertrophy in hypertrophic cardiomyopathy and its differential diagnosis. Curr. Opin. Cardiol. (IF 2.3) Pub Date : 2023-07-07 Lana Rashdan,James Hodovan,Ahmad Masri
PURPOSE OF REVIEW The aim of this study was to review imaging of myocardial hypertrophy in hypertrophic cardiomyopathy (HCM) and its phenocopies. The introduction of cardiac myosin inhibitors in HCM has emphasized the need for careful evaluation of the underlying cause of myocardial hypertrophy. RECENT FINDINGS Advances in imaging of myocardial hypertrophy have focused on improving precision, diagnosis
-
Monitoring treatment with cardiac myosin inhibitors in symptomatic obstructive cardiomyopathy. Curr. Opin. Cardiol. (IF 2.3) Pub Date : 2023-06-27 Safia Chatur, Sheila M Hegde
Cardiac myosin inhibitors (CMIs) represent a major milestone in the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. The objective of this review is to discuss the mechanisms of action, clinical trial evidence, safety profile and monitoring of CMIs, which are important to the implementation of these drugs in clinical practice.
-
Editorial: from albuminuria to uric acid - emerging risk factors beyond lipids. Curr. Opin. Cardiol. (IF 2.3) Pub Date : 2023-07-01 Debabrata Mukherjee,Dimitri P Mikhailidis
-
Unanswered questions on coronary artery graft patency and clinical outcomes. Curr. Opin. Cardiol. (IF 2.3) Pub Date : 2023-05-22 Lamia Harik, Sigrid Sandner, Mario Gaudino
To review current issues related to coronary artery graft patency and outcomes.
-
Sleep apnea and cardiovascular risk. Curr. Opin. Cardiol. (IF 2.3) Pub Date : 2023-05-19 Manu Rajachandran, Nils Nickel, Richard A Lange
Obstructive sleep apnea (OSA) is associated with several cardiovascular risk predictors that have only recently begun to be studied in detail. The strong association between OSA and hypertension, coronary artery disease, congestive heart failure, and sudden cardiac death underscores its significant impact on cardiovascular health. This brief review considers the links between OSA and cardiovascular
-
Understanding the next circulation: lymphatics and what the future holds. Curr. Opin. Cardiol. (IF 2.3) Pub Date : 2023-05-09 Catherine E Tomasulo,Yoav Dori,Christopher L Smith
PURPOSE OF REVIEW The lymphatic system was previously considered the forgotten circulation because of an absence of adequate options for imaging and intervention. However, recent advances over the last decade have improved management strategies for patients with lymphatic disease, including chylothorax, plastic bronchitis, ascites, and protein-losing enteropathy. RECENT FINDINGS New imaging modalities
-
Multimodality cardiovascular imaging in hypertension Curr. Opin. Cardiol. (IF 2.3) Pub Date : 2023-04-28 Tiffany Dong, Christian Faaborg-Andersen, Mariana Garcia, Michael Blaha, Allan L. Klein, Edward Gill, Raymundo A. Quintana
Purpose of the review Hypertension accounts for the largest proportion of cardiovascular (CV) mortality worldwide and its prevalence continues to rise. While prominent CV societies have offered strong recommendations on the management of hypertension in adults, the role of noninvasive CV imaging in the evaluation of hypertensive patients remains incompletely defined. Recent findings Noninvasive imaging